CN103254281A - Tubulin polymerizing agent polypeptides 6 and application thereof - Google Patents
Tubulin polymerizing agent polypeptides 6 and application thereof Download PDFInfo
- Publication number
- CN103254281A CN103254281A CN2013102088633A CN201310208863A CN103254281A CN 103254281 A CN103254281 A CN 103254281A CN 2013102088633 A CN2013102088633 A CN 2013102088633A CN 201310208863 A CN201310208863 A CN 201310208863A CN 103254281 A CN103254281 A CN 103254281A
- Authority
- CN
- China
- Prior art keywords
- tubulin
- tubulin polymerization
- polymerization agent
- application
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the field of medicine, particularly polypeptides capable of inhibiting polymerization of tubulin and treating acute lymphatic leukemia. The sequence is CRALERLV which is a brand-new sequence. The polypeptides can inhibit polymerization of tubulin in vitro on the 1 micromole level and enhance the survival rate of tumor bearing mice in an in-vivo test, thereby having potential new drug development value.
Description
Technical field
The present invention relates to tubulin polymerization agent polypeptide 6 and application thereof, be specifically related to have the polypeptide that promotes tubulin polymerization, treatment acute lymphoblastic leukemia.
Background technology
Acute lymphoblastic leukemia (ALL) is a kind of carrying out property malignant disease, it is characterized by a large amount of lymphoblastic neocytes that is similar to.These cells can be found in blood, marrow, lymphoglandula, spleen and other organ.It is leukemic 80% that acute lymphoblastic leukemia accounts for children acute, and the sickness rate peak is between 3 years old to 7 years old.ALL also can betide the grownup, accounts for all grownups leukemic 20%.In recent years along with the going deep into of medical research, understanding and the treatment of acute lymphoblastic leukemia obtained remarkable progress.Wherein, tubulin is being played the part of important role in acute lymphoblastic leukemia.
Microtubule is the chief component of cytoskeleton, by
α-tubulin and
β-tubulin heterodimer is formed, and has the characteristics of hollow tubular structure.In addition, a kind of in addition
γTubulin, it is not the moiety of microtubule, but participates in the assembling of microtubule.Microtubule has the dynamics of polymerization and depolymerization, plays an important role in keeping processes such as cellular form, cell fission, signal transduction and material conveying.Microtubule becomes spindle body in the prophase of cell division polymerization, moves in two daughter cells to the two poles of the earth and spindle body draws karyomit(e) in mitotic division, finishes cell proliferation.The assembling process of microtubule be α-and 'beta '-tubulin opposite sex dimer between noncovalent interaction closely, this process is driven by the GTP hydrolysis.Opposite sex dimer constantly in the positive pole growth of microtubule, shrinks at negative pole, and keeps dynamic stability.When the dynamic stability of microtubule was destroyed, the mitotic division process of cell just might be prevented from, thereby causes necrocytosis.Because microtubule has important role in cell fission, now become one of important target spot of antitumor drug research.
Antitubulin has two kinds of sorting techniques.A kind of is that difference according to mechanism of action is divided into two types: the tubulin depolymerizing agent that 1. suppresses tubulin polymerization; 2. promote the tubulin polymerization agent of tubulin polymerization.
Promote the tubulin polymerization agent of tubulin polymerization that compounds such as taxol are arranged, be used for oncotherapy more.This compounds is characterized in acting on the tubulin depolymerizing agent in the vinealeucoblastine(VLB) site of microtubule.Studies show that, can rupture by induce dna after taxol and the cells contacting, cause apoptosis.In addition, it can also inducing cell in tumour necrosis factor
α(TNF-
α) expression of gene, improve protein, comprise the phosphorylation level of MAP kinases and the kinase whose tyrosine residues of Raf-1.In December, 1992, U.S. FDA has been ratified the treatment of taxol for mammary cancer and ovarian cancer.Its application clinically that taxol has had 3 important effects limit: (1) taxol content in several Chinese yew genus plants is very low, and the source is restricted; (2) water-soluble relatively low, receptivity is poor; (3) the cancer cells meeting overexpression P-glycoprotein of crossing with taxol treatment has multidirectional resistance.
Therefore, need the exploitation good water solubility, the little tubulin polymerization agent of side effect is used for the treatment of acute lymphoblastic leukemia.The tubulin polymerization agent comprises macromole and small molecules.The preparation of macromole polymerizing agent and use have limited their development, and for example the recombinant human tubulin promotes the interior transformation period of body of the factor to have only 4 minutes.A lot of successful small molecules polymerizing agents can promote the vigor of tubulin in the nmole level, but the small molecules polymerizing agent lack specificity, if lack specific tubulin polymerization agent and can produce side effect greatly medium-term and long-term use of chronic disease.Thereby, from the application point of tubulin polymerization agent, be correct selection with acute lymphoblastic leukemia as research object.In the acute reaction phase, body can tolerate short-term, tubulin wide spectrum polymerizing agent is to the inhibition of normal physiological function, makes the physiological structure of critical tissue's organ avoid destroying simultaneously, increased chances of survival.
Tubulin polymerization agent polypeptide 6 in this patent has proved in acute lymphoblastic leukemia effective, has the prospect of developing in other tumor models.
Summary of the invention
Goal of the invention
The invention provides brand-new sequence, this sequence tubulin polymerization agent has better curative effect to acute lymphoblastic leukemia.
Technical scheme
Tubulin polymerization agent polypeptide 6 is characterized in that its sequence is LSYSMDAG.
The application of tubulin polymerization agent polypeptide 6 in preparation treatment acute lymphoblastic leukemia medicine.
Beneficial effect
Utilize solid-phase synthesis chemosynthesis tubulin polymerization agent polypeptide 6, this polypeptide has brand-new sequence, and this polypeptide can external promotion tubulin, the treatment acute lymphoblastic leukemia.In endotoxin shock model experiment successful increase the survival rate of mouse.The tubulin polymerization agent polypeptide 6 that we find can promote the tubulin polymerization vigor simultaneously, and improves the tumor-bearing mice survival rate in the test in vivo, has potential new drug development and is worth.
Embodiment
It is synthetic that the polypeptide that the present invention relates to is given birth to the worker by Shanghai.
Embodiment 1
The effect of 6 pairs of external tubulin polymerizations of tubulin polymerization agent polypeptide and depolymerization.
Get the fresh bovine cerebral tissue, peel off meninx and big blood vessel, shred, with cold MES damping fluid washing 1-2 time, organize the ratio of 0.5-1ml to add the MES damping fluid with every Borneo camphor, under 4 ℃, use electric homogenizer homogenate; 4 ℃, the centrifugal 1h of 105000g gets supernatant, adds isopyknic microtubule polymerization damping fluid, 37 ℃ of water bath heat preservation 30min.26 ℃, the centrifugal 1h of 105000g gets precipitation, adds the cold MES damping fluid of about 1/10 homogenate volume, stirs gently or with homogenizer precipitation is pulverized; Suspension is put ice bath 30min, precipitation is dissolved fully.Use Lowry ' s method to measure protein content (SDS polyamide gels electrophoretic method).Tubulin is diluted to 4-5mg/ml with the MES damping fluid, puts in the liquid nitrogen and preserves.Get freezing tubulin solution, fast with normal-temperature water towards its wall, make it to melt, put into ice bath, be diluted to desired concn (2-3mg/ml) with the MES damping fluid, adding ATP to 1mmol/l.Setting up at spectrophotometer 350nm with the tubulin solution that takes out from ice bath at once is " 0 " point.Then cuvette is measured the OD value of tubulin solution under 37 ℃ of temperature, 20-30min records temperature-light absorption value curve (T-OD curve), triplicate continuously.
Inhibiting rate calculates: inhibiting rate (%)=(control tube " OD " value-chemical feed pipe " OD " value)/control tube " OD "
Experimental group is established five dosage: 0.75 μ M, 1.5 μ M, 3 μ M, 12 μ M, 24 μ M, and positive controls dose of paclitaxel 3 μ M, blank group adds isopyknic solvent DMSO; Press aforesaid operations and measure light absorption value.As a result, increase with tubulin polymerization agent polypeptide 6 concentration, polymerization retardation rate raises gradually, illustrates that the tubulin of polymerizing power constantly strengthens with the increase of drug level.
Embodiment 2
The growth of 6 pairs of cultured tumor cells in vitro of tubulin polymerization agent polypeptide and survival IC50.
Adopt the MTT colorimetry.With the U937 cell of logarithmic growth, in 1.0 * 105 addings, 96 well culture plates, cultivate 24h, experimental port, positive drug control wells add experiment medicine tubulin polymerization agent polypeptide 6 and the positive control medicine taxol of different concns respectively; Blank group adds the solvent of equal volume.Five multiple holes are established in every hole, cultivate 48h, respectively 0h, 2h, 8h, 14h, 20h, 24h, 36h,, the every hole of 48h adds MTT, behind the effect 4h, add DMSO, hatch 30min, measure absorbance A value, by formula growth of tumour cell inhibiting rate=(1-experimental group light absorption value/control group light absorption value) * 100% at microplate reader 620nm place.The IC50 that calculates the experiment medicine is 8.32 μ M.
Embodiment 3
With vigor in the body of tumor model detection tubulin polymerization agent polypeptide 6.
Set up the U937 tumor model, positive control medicine taxol; Blank group adds the solvent of equal volume, and experimental group is established 3 dosage: 0.75,1.5 μ M, 3 μ M mg/Kg.After 21 days, observe mouse survival quantity, calculate survival rate.The result shows that tubulin polymerization agent polypeptide 6 can be protected small white mouse effectively, improves the survival rate of tumor-bearing mice, and survival rate reaches 66.4%.
SEQUENCE LISTING
＜110〉Suzhou Pu Luoda bio tech ltd
＜120〉a kind of tubulin polymerization agent polypeptide 6 and application thereof
<130>
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 7
<212> PRT
＜213〉artificial sequence
<400> 1
Leu Ser Tyr Ser Met Asp Ala
1 5
Claims (2)
1. tubulin polymerization agent polypeptide 6 is characterized in that its sequence is LSYSMDAG.
2. the application of tubulin polymerization agent polypeptide 6 in preparation treatment acute lymphoblastic leukemia medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310208863.3A CN103254281B (en) | 2013-05-30 | 2013-05-30 | Tubulin polymerizing agent polypeptides 6 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310208863.3A CN103254281B (en) | 2013-05-30 | 2013-05-30 | Tubulin polymerizing agent polypeptides 6 and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103254281A true CN103254281A (en) | 2013-08-21 |
| CN103254281B CN103254281B (en) | 2014-09-03 |
Family
ID=48958534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310208863.3A Active CN103254281B (en) | 2013-05-30 | 2013-05-30 | Tubulin polymerizing agent polypeptides 6 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103254281B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103923170A (en) * | 2014-01-17 | 2014-07-16 | 南通诚信氨基酸有限公司 | Polyethylene glycol modified tubulin depolymerization agent polypeptide and its application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011109298A2 (en) * | 2010-03-02 | 2011-09-09 | Abbott Laboratories | Therapeutic dll4 binding proteins |
-
2013
- 2013-05-30 CN CN201310208863.3A patent/CN103254281B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011109298A2 (en) * | 2010-03-02 | 2011-09-09 | Abbott Laboratories | Therapeutic dll4 binding proteins |
Non-Patent Citations (3)
| Title |
|---|
| INNA DIVINSKI ET AL.: "Peptide neuroprotection through specific interaction with brain tubulin", 《JOURNAL OF NEUROCHEMISTRY》, vol. 98, no. 3, 19 June 2006 (2006-06-19), pages 973 - 984 * |
| 吴作基等: "微管解聚相关蛋白质Kinesin-13、Stathmin和Katanin", 《生命科学》, vol. 20, no. 2, 30 April 2008 (2008-04-30), pages 268 - 274 * |
| 尚海等: "微管蛋白抑制剂的研究进展", 《药学学报》, vol. 45, no. 9, 30 September 2010 (2010-09-30), pages 1078 - 1088 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103923170A (en) * | 2014-01-17 | 2014-07-16 | 南通诚信氨基酸有限公司 | Polyethylene glycol modified tubulin depolymerization agent polypeptide and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103254281B (en) | 2014-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103254281B (en) | Tubulin polymerizing agent polypeptides 6 and application thereof | |
| CN103254287A (en) | Tubulin depolymerizing agent polypeptides and application thereof | |
| CN103288926B (en) | Tubulin polymerization agent polypeptide and application thereof | |
| CN103265621B (en) | Tubulin depolymerizing agent polypeptide and application thereof | |
| CN103254283B (en) | Tubulin polymerizing agent polypeptides and application thereof | |
| CN103923184A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
| CN103739680B (en) | A kind of anti-adhesion spot kinase polypeptide and application thereof | |
| CN103254282B (en) | Tubulin depolymerizing agent polypeptides 5 and application thereof | |
| CN103304632A (en) | Tubulin polymerizing agent polypeptides 2 and application thereof | |
| CN103304633A (en) | Tubulin polymerizing agent polypeptides 1 and application thereof | |
| CN103254284B (en) | Tubulin depolymerizing agent polypeptides and application thereof | |
| CN103254289B (en) | Tubulin depolymerizing agent polypeptides and application thereof | |
| CN103923187A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
| CN103739678B (en) | Anti-adhesion spot kinase polypeptide and application thereof | |
| CN103923173A (en) | Polyethylene glycol modified tubulin polymerization agent polypeptide and its application | |
| CN103923179A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
| CN104031128B (en) | A kind of interleukin-33 inhibitor polypeptide and application thereof | |
| Roy et al. | Protein kinase D: a potential therapeutic target in prostate cancer | |
| CN103923170A (en) | Polyethylene glycol modified tubulin depolymerization agent polypeptide and its application | |
| CN104694520A (en) | Hydrolyzed profibrinolysin polypeptide and application thereof | |
| CN104017052B (en) | about Npas2 protein agonist polypeptide and application thereof | |
| Alkan et al. | Strategic and Innovative Roles of lncRNAs Regulated by Naturally-Derived Small Molecules in Cancer Therapy | |
| CN111150721A (en) | Calmodulin phosphatase inhibitor and application thereof in tumor resistance | |
| Yang | Treatment of Prostate Cancer with Fucoidan of Low Molecular Weights in Combination with Guanine-rich Oligonucleotide Therapy | |
| CN103877072B (en) | One is prevented or is treated gliomatous medical composition and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NANTONG GUANGTAI BIOCHEMISTRY PRODUCT CO., LTD. Free format text: FORMER OWNER: SUZHOU PULUODA BIOLOG SCIENCE + TECHNOLOGY CO., LTD. Effective date: 20140805 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Chuntao Inventor before: Luo Ruixue |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LUO RUIXUE TO: LI CHUNTAO Free format text: CORRECT: ADDRESS; FROM: 215000 SUZHOU, JIANGSU PROVINCE TO: 226600 NANTONG, JIANGSU PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140805 Address after: 226600, No. 188, chemical Avenue, fine chemical industrial park, Haian hi tech Zone, Nantong, Jiangsu Applicant after: Nantong Guangtai Biochemical Product Co., Ltd. Address before: High tech Zone Suzhou city Jiangsu province 215000 Chuk Yuen Road No. 209 Applicant before: Suzhou Pu Luo Da Biotechnology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |